Actively Recruiting
NCCR AntiResist: Mono-center Study to Identify New Approaches to Combat Antibiotic-resistant Bacteria.
Led by University Hospital, Basel, Switzerland · Updated on 2025-03-04
8000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University Hospital, Basel, Switzerland
Lead Sponsor
S
Swiss National Science Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are exploring antimicrobial resistance (AMR) by studying patient samples at the University Hospital of Basel. This study focuses on three types of infections: urinary tract infection, pneumonia, and deep-seated infections caused by four key bacteria listed by the World Health Organization as high priority: E. coli, Klebsiella species, S. aureus, and P. aeruginosa. The goal is to understand the physiological traits of these bacteria in human infections and to support new strategies against antibiotic-resistant bacteria through a multidisciplinary approach involving clinicians and scientists. The study processes residual patient samples including urine, tracheal secretions, bronchioalveolar lavage, and intraoperative materials for various analyses such as proteomic, metabolomic, transcriptomic, immunocytochemical, fluorescence in-situ hybridization, flow cytometry, and immunophenotyping. Samples testing positive for the target bacteria are stored in a biobank. Additional evaluations include bacterial property exploration, mass spectrometry, whole genome sequencing, and analysis of virulence factors and immune responses. Clinical and epidemiological data are also collected. The study includes control groups with and without infection samples and investigates whether certain legal provisions can reduce bias in the study population. Participants' residual samples are analyzed alongside their clinical, microbiological, and laboratory data. Researchers assess outcomes such as survival rate, mortality rate, and treatment response at baseline. The study also involves storing plasma samples for patients previously treated with antibiotics. Data from this study will help correlate clinical outcomes with bacterial and host characteristics. The study is ongoing with no maximum age limit and includes adults aged 18 and older. The total duration and follow-up vary depending on the patient and sample availability.
CONDITIONS
Brief Title
NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years and older
- Patients with confirmed urinary tract infection caused by E. coli, Klebsiella species, S. aureus, or P. aeruginosa
- Patients with confirmed pneumonia (including post-lung transplantation or cystic fibrosis) caused by the listed bacteria
- Patients with confirmed deep-seated infection caused by the listed bacteria
- Controls with no detectable bacteria or infection site and with signed general consent
- Clinical controls with confirmed infections as above but without obtained samples
- Signed general consent for research use
You will not qualify if you...
- Patients who have refused research consent or reuse of their data/samples
- Patients with infections caused by bacteria other than E. coli, Klebsiella species, S. aureus, or P. aeruginosa
- Age under 18 years
- Controls without signed general consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single timepoint at baseline
Participants provide residual clinical samples such as urine, tracheal secretions, bronchioalveolar lavage, or intraoperative materials for detailed analysis of bacterial pathogens and host responses. Clinical data including demographics and microbiological data are also collected.
1 visit (in-person)
Duration - Up to study completion in December 2028
Participants are observed through analysis of collected samples and clinical data to investigate bacterial pathogen physiology and clinical outcomes such as survival and treatment response.
No additional visits required; observational follow-up through data analysis
Trial Site Locations
Total: 1 location
1
University Hospital Basel
Basel, Switzerland, 4031
Actively Recruiting
Research Team
N
Nina Khanna, Prof.
C
Christoph Dehio, Prof.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
6
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here